propionamide has been researched along with Gastrointestinal Stromal Tumors in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, M; Chen, C; Hu, C; Hu, Z; Li, B; Liu, F; Liu, J; Liu, Q; Liu, X; Qi, Z; Ren, T; Wang, A; Wang, B; Wang, L; Wang, W; Wu, H; Wu, J; Ye, L; Yu, K; Zhang, S; Zou, F | 1 |
1 other study(ies) available for propionamide and Gastrointestinal Stromal Tumors
| Article | Year |
|---|---|
Discovery of N-((1-(4-(3-(3-((6,7-Dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I "Gatekeeper" Mutant of cKIT Kina
Topics: Amides; Animals; Cell Line, Tumor; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Halogenation; Humans; Methylation; Mice; Mice, Nude; Models, Molecular; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Rats, Sprague-Dawley; Structure-Activity Relationship | 2016 |